25 related articles for article (PubMed ID: 19619445)
1. Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial.
Ali HR; Dariush A; Thomas J; Provenzano E; Dunn J; Hiller L; Vallier AL; Abraham J; Piper T; Bartlett JMS; Cameron DA; Hayward L; Brenton JD; Pharoah PDP; Irwin MJ; Walton NA; Earl HM; Caldas C
Ann Oncol; 2017 Aug; 28(8):1832-1835. PubMed ID: 28525534
[TBL] [Abstract][Full Text] [Related]
2. Coagulation factor V in breast cancer: a p53-regulated tumor suppressor and predictive marker for treatment response to chemotherapy.
Lind SM; Sletten M; Hellenes M; Mathelier A; Tekpli X; Tinholt M; Iversen N
J Thromb Haemost; 2024 Jun; 22(6):1569-1582. PubMed ID: 38382738
[TBL] [Abstract][Full Text] [Related]
3. Designing adjuvant treatment based on biological measurements in the neoadjuvant setting.
Smith IE; Kotsori A
Breast Cancer Res; 2010 Dec; 12 Suppl 4(Suppl 4):S16. PubMed ID: 21172078
[No Abstract] [Full Text] [Related]
4. Latissimus dorsi myocutaneous flap repair is effective after neoadjuvant chemotherapy for locally advanced breast cancer.
Li L; Yang Y; Li W; Zhao X; He J; Mei S; Guo X; Zhang X; Ran J
World J Surg Oncol; 2022 Apr; 20(1):134. PubMed ID: 35477520
[TBL] [Abstract][Full Text] [Related]
5. Inflammatory breast cancer-comparing the effectivity of preoperative docetaxel-epirubicine protocol to conventional antracycline-containing chemotherapy to achieve clinical benefit and complete pathological response.
Horváth Z; Torday L; Hitre E; Ganofszky E; Juhos E; Czeglédi F; Urbán L; Polgár C; Láng I; Eckhardt S; Kásler M
Pathol Oncol Res; 2011 Sep; 17(3):541-50. PubMed ID: 21153723
[TBL] [Abstract][Full Text] [Related]
6. Medical treatment of early breast cancer. III: chemotherapy.
Smith I; Chua S
BMJ; 2006 Jan; 332(7534):161-2. PubMed ID: 16424494
[No Abstract] [Full Text] [Related]
7. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer.
Pierga JY; Mouret E; Diéras V; Laurence V; Beuzeboc P; Dorval T; Palangié T; Jouve M; Vincent-Salomon A; Scholl S; Extra JM; Asselain B; Pouillart P
Br J Cancer; 2000 Dec; 83(11):1480-7. PubMed ID: 11076657
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy analysis of THP-containing regimens as neoadjuvant and adjuvant chemotherapy for primary breast cancer].
Wang LZ; Ouyang T; Wang TF; Xie YT; Fan ZQ; Fan T; Lin BY; Li JF
Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):143-6. PubMed ID: 22780935
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of two different regimens as neoadjuvant chemotherapy for breast cancer].
Yang D; Tong F; Cao Y; Liu P; Zhou B; Liu H; Qiao X; Zhang J
Zhonghua Zhong Liu Za Zhi; 2002 May; 24(3):303-5. PubMed ID: 12515634
[TBL] [Abstract][Full Text] [Related]
11. [Comparative study of chemosensitivity and efficacy between pirarubicin and epirubicin in breast cancer].
Zang MF; Zhang YM; Zhi YH; Zhai Z; Zhang M; Gu F; Zhi XC
Zhonghua Yi Xue Za Zhi; 2011 May; 91(20):1388-92. PubMed ID: 21756809
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of neoadjuvant chemotherapy with FEC and TEC regimen on breast cancer].
Wang B; Fu JF; Hong ZW
Ai Zheng; 2009 Mar; 28(3):292-6. PubMed ID: 19619445
[TBL] [Abstract][Full Text] [Related]
13. Invasive ductal carcinoma within a fibroadenoma of the breast.
Abe H; Hanasawa K; Naitoh H; Endo Y; Tani T; Kushima R
Int J Clin Oncol; 2004 Aug; 9(4):334-8. PubMed ID: 15375712
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
